O Keefe Stevens Advisory Inc. Has $1.88 Million Stake in Pfizer Inc. (NYSE:PFE)

O Keefe Stevens Advisory Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,868 shares of the biopharmaceutical company’s stock after buying an additional 12,567 shares during the quarter. Pfizer comprises 0.6% of O Keefe Stevens Advisory Inc.’s portfolio, making the stock its 27th biggest position. O Keefe Stevens Advisory Inc.’s holdings in Pfizer were worth $1,877,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth $29,000. Quarry LP bought a new position in Pfizer during the second quarter worth about $31,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC increased its stake in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE opened at $29.18 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company’s fifty day simple moving average is $29.14 and its 200 day simple moving average is $28.33. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92. The company has a market cap of $165.35 billion, a price-to-earnings ratio of -486.33, a PEG ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business earned $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Thursday, October 3rd. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.